东方田鼠室内繁殖与生长发育观察

近年来,逐渐增多的小鼠突变系资源已对现有的动物设施和品种（系）的保存方法提出严峻的挑战,小鼠胚胎和配合子的低温保存是目前保存小鼠种群资源中应用最为广泛的方法,通过低温保存不仅使原有的或新开发的小鼠品系得以安全的,长期的保存下来,同时也使这些小 模型的规模化生产,推广普及变得更为简单化,无疑,小鼠模型的保存将为21世纪哺乳类遗传学的飞速发展和最终攻克人类目前的疑难疾病创造了有利条件。     

高血压病以昼夜血压模式指导治疗初探

目的：探讨高血压以昼夜血压模式指导药物治疗的疗效。方法：124例高血压患者被随机分为两组：观察组80例,采用以昼夜血压模式为依据,指导选用药物进行治疗,着重加强异常升高血压部份的降压治疗,同时加强血压监测;对照组仍按照常规方法治疗,6周为1疗程,治疗前和治疗后都检测血压和24小时动态血压。结果：观察组降压的总有效率和昼夜血压模式转为正常杓形态明显高于对照组,结论：高血压病患者以昼夜血压模式为依据指导用药降压治疗有较好的医疗效果。     

Kubelka-Munk模型下的兔血管对氦-氖激光的散射与吸收特性

测量了兔动脉和静脉对 He-Ne激光的反射和透射传输特性。实验采用两积分球系统及波长为632.8nm的He-Ne激光器,并根据测量数据及采用 Kubelka-Munk模型分析和计算了兔动脉和静脉组织对该长激光的吸收系数、散射系数及总的光强I（x）及前向散射通量i(x）和后向散射通量j(x）随厚度的变化情况。结果表明,兔动脉和静脉的漫反射率和透射率有明显差别,而且,动脉对激光的吸收系数明显较静脉的要小,而动脉对激光的散射系数却明显较静脉的要大,在动脉和静脉组织中总的光强I（x）及前向散射通量i(x）和后向散射通量j(x）随组织厚度的变化情况也有明显的区别。     

腹膜透析相关性腹膜炎兔模型的病理形态学观察

用 12只新西兰大白兔分为腹膜炎组和对照组。腹膜炎组注射含活金黄色葡萄球菌的透析液 ,对照组为含生理盐水的透析液 ;观察腹膜透析相关性腹膜炎兔模型的病理变化。结果发现 :(1)腹膜炎组腹膜间皮细胞增生 ,水肿 ,血管扩张 ,炎症细胞浸润 ,对照组无变化。 (2 )腹膜炎组腹膜透液中葡萄糖浓度除 0min外 ,其他各时间点D/D0 葡萄糖均低于对照组 (P <0 .0 1)。 (3)腹膜炎组腹透液中肌酐浓度与血浆肌酐浓度比值 (D/Dcr)显著高于对照组中的浓度比值 (P <0 .0 5 )。 (4 )腹膜炎组透析液中WBC计数除O点外 ,其余各时间点明显高于对照组 (P <0 .0 5 )。提示新西兰兔腹膜注射含活金黄色葡萄球菌 48h后 ,进行腹膜透析时 ,其腹膜病理改变与临床腹膜透析并发腹膜炎特征基本一致     

大鼠磨牙三维有限元模型的建立

目的 :建立大鼠磨牙的三维有限元模型 ,探讨牙及牙周组织的应力分布状况。方法 :采用Sprague Dawley大鼠 2 0只 ,建立大鼠磨牙正畸移动的动物模型 ,制作大鼠上颌第一磨牙牙周连续切片 ;采用计算机技术 ,重建牙及牙周组织三维形态、结构 ,并建立其三维有限元模型。结果 :组织切片的应力分布显示牙周膜是一种存在于两种硬组织之间的软组织 ,有其特有的应力分布状态。结论 :本研究建立的正畸大鼠磨牙三维有限元模型是观察正畸牙移动过程中分析应力的一种简便、准确、可靠的模型及方法。     

Measuring quality and outcomes in intensive care

While quality measures are integral to the maintenance of a high standard of patient care, high-quality care remains a complicated concept to define in the context of acute care. In this article we explore how quality can be measured in the intensive care unit. Standard outcome metrics such as mortality are tangible comparators, but do not offer a comprehensive assessment of quality for the complex heterogeneity of the intensive care population. We explore the Donabedian model as a means to describe the importance of outcomes, processes, structure and environment to inform the measurement of quality. These concepts can be more abstract and difficult to measure but can provide significant insight into the culture of a unit and the resulting performance, and thus provide a more comprehensive measure of quality.     

Mathematical model of volume kinetics and renal function after burn injury and resuscitation

This paper presents a mathematical model of blood volume kinetics and renal function in response to burn injury and resuscitation, which is applicable to the development and non-clinical testing of burn resuscitation protocols and algorithms. Prior mathematical models of burn injury and resuscitation are not ideally suited to such applications due to their limited credibility in predicting blood volume and urinary output observed in wide-ranging burn patients as well as in incorporating contemporary knowledge of burn pathophysiology. Our mathematical model consists of an established multi-compartmental model of blood volume kinetics, a hybrid mechanistic-phenomenological model of renal function, and novel lumped-parameter models of burn-induced perturbations in volume kinetics and renal function equipped with contemporary knowledge on burn-related physiology and pathophysiology. Using the dataset collected from 16 sheep, we showed that our mathematical model can be characterized with physiologically plausible parameter values to accurately predict blood volume kinetic and renal function responses to burn injury and resuscitation on an individual basis against a wide range of pathophysiological variability. Pending validation in humans, our mathematical model may serve as an effective basis for in-depth understanding of complex burn-induced volume kinetic and renal function responses as well as development and non-clinical testing of burn resuscitation protocols and algorithms.     

Development and Validation of Scoring Indication of Surgical Clipping and Endovascular Coiling for Aneurysmal Subarachnoid Hemorrhage from the Post Hoc Analysis of Japan Stroke Data Bank

There are no scoring methods for optimal treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH). We developed a scoring model to predict clinical outcomes according to aSAH risk factors using data from the Japan Stroke Data Bank (JSDB). Of 5344 patients initially registered in the JSDB, 3547 met the inclusion criteria. Patients had been diagnosed with aSAH and treated with surgical clipping or endovascular coiling between 1998 and 2013. We performed multivariate logistic regression for poor outcomes at discharge, indicated by a modified Rankin Scale (mRS) score >2, and in-hospital mortality for both treatment methods. Based on each risk factor, we developed a scoring model assessing its validity using another dataset of our institution. In the surgical clipping group, scoring criteria for aSAH were age >72 years, history of more than once stroke, World Federation of Neurological Societies (WFNS) grades II–V, aneurysmal size >15 mm, and vertebrobasilar artery (VBA) aneurysm location. In the endovascular coiling group, scoring criteria were age >80 years, history of stroke, WFNS grades III–V, computed tomography (CT) Fisher group 4, and aneurysmal location in the middle cerebral artery (MCA) and anterior cerebral artery (ACA). The rates of poor outcome of mRS score >2 in an isolated dataset using these scoring criteria were significantly correlated with our model’s scores, so this scoring model was validated. This scoring model can help in the more objective treatment selection in patients with aSAH.     

Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients

Outcomes following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative recipients with HCV treatment are good. We assessed cost-effectiveness between cohorts of transplant recipients willing and unwilling to receive HCV-viremic hearts. Markov model simulated long-term outcomes among HCV-negative patients on the transplant waitlist. We compared costs (2018 USD) and health outcomes (quality-adjusted life-years, QALYs) between cohorts willing to accept any heart and those willing to accept only HCV-negative hearts. We assumed 4.9% HCV-viremic donor prevalence. Patients receiving HCV-viremic hearts were treated, assuming $39 600/treatment with 95% cure. Incremental cost-effectiveness ratios (ICERs) were compared to a $100 000/QALY gained willingness-to-pay threshold. Sensitivity analyses included stratification by blood type or region and potential negative consequences of receipt of HCV-viremic hearts. Compared to accepting only HCV-negative hearts, accepting any heart gained 0.14 life-years and 0.11 QALYs, while increasing costs by $9418/patient. Accepting any heart was cost effective (ICER $85 602/QALY gained). Results were robust to all transplant regions and blood types, except type AB. Accepting any heart remained cost effective provided posttransplant mortality and costs among those receiving HCV-viremic hearts were not >7% higher compared to HCV-negative hearts. Willingness to accept HCV-viremic hearts for transplantation into HCV-negative recipients is cost effective and improves clinical outcomes.